Jenifer H. Voeks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jenifer H. Voeks has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Thomas G. Brott
Department of Neurology Mayo Clinic Jacksonville FL
9 shared publications - George Howard
University of Alabama at Birmingham
7 shared publications - Virginia J. Howard
University of Alabama at Birmingham
5 shared publications Gary S. Roubin
4 shared publications- James F. Meschia
Department of Neurology, Mayo Clinic, Jacksonville, FL
4 shared publications - Bret M. Hanlon
University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA
3 shared publications
Latest Publications
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200509
Psychosis in Neurocognitive Disorder Among Ethnoculturally Diverse Older Persons
[This corrects the article DOI: 10.1212/CPJ.0000000000200467.].
- 1 August 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (4) , e200509
Psychosis in Neurocognitive Disorder Among Ethnoculturally Diverse Older Persons
[This corrects the article DOI: 10.1212/CPJ.0000000000200467.].
- 1 June 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (3) , e200467
Psychosis in Neurocognitive Disorder Among Ethnoculturally Diverse Older Persons
There is longstanding evidence that the presence of psychosis in neurocognitive disorders (NCDs) is associated with faster cognitive and functional decline. The goal of this study was to examine how clinician-diagnosed psychosis differs among ethnoracial groups with NCDs (including early onset) and to explore whether these differences exist even for those without advanced dementia. This is an IRB-approved retrospective analysis. Data are from the National Alzheimer's Coordinating Center Uniform Dataset from 42 Alzheimer's Disease Research Centers. Participants aged 40–95 years as of June 2023 with mild cognitive impairment (MCI) or dementia on baseline evaluation were included. Psychosis was defined as clinician-diagnosed visual or auditory hallucinations or delusions manifesting at the time of baseline evaluation. Ethnoracial groups were self-reported. Associations between ethnoracial groups and psychosis in NCDs were estimated using adjusted multivariable logistic regression with dichotomous measures of outcomes. Covariates included age, sex, years of education, severity of cognitive impairment (Clinical Dementia Rating scale), and presence or absence of any self-reported preexisting psychiatric illness. An analysis by age younger than 65 years was also conducted. Exploratory multivariable logistic regression analyses were performed for participants with milder stages of dementia (Clinical Dementia Rating 0.5 or 1) and for the subset of participants diagnosed with MCI. A total of 22,854 participants were included. The mean age was 73 + 9.7 years, and 50% were women. A total of 8,352 (37%) had MCI and 14,502 (63%) had dementia. In adjusted analysis, American Indian/Alaska Native (AI/AN) (OR 2.70, 1.75–4.17, p < 0.0001), Black-Latino (OR 2.33, 1.25–4.35, p = 0.0076), Other-Latino (OR 1.82, 1.42–2.33, p < 0.0001), Black, non-Latino (NL) (OR 1.66,1.47–1.87, p < 0.0001), and White-Latino (OR 1.42, 1.21–1.67, p < 0.0001) participants had greater odds of any psychotic symptom than White-NL participants. For age groups 40 to younger than 65 years, only Black-NL participants (OR 1.56, 1.13–2.14, p = 0.0064) were more likely to be diagnosed with any psychotic symptoms. For milder stages of dementia, Black-Latino (OR 3.44, 1.58–7.48, p = 0.0018), AI/AN (OR 2.73, 1.66–4.48, p < 0.0001), Other-Latino (OR 2.38, 1.72–3.30, p < 0.0001), Black-NL (OR 2.08,1.77–2.45, p < 0.0001), and White-Latino (OR 1.55, 1.23–1.95, p = 0.0002) participants had greater odds of psychosis in NCDs when compared with White-NL participants. For MCI alone, there were no significant differences. Black-NL, Latino, and AI/AN individuals were more likely to be diagnosed with psychosis in NCDs when compared with White-NL participants. More research is needed to explore sociocultural, psychosocial, and neuropathologic factors involved.
- 1 June 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (3) , e200467
Psychosis in Neurocognitive Disorder Among Ethnoculturally Diverse Older Persons
There is longstanding evidence that the presence of psychosis in neurocognitive disorders (NCDs) is associated with faster cognitive and functional decline. The goal of this study was to examine how clinician-diagnosed psychosis differs among ethnoracial groups with NCDs (including early onset) and to explore whether these differences exist even for those without advanced dementia. This is an IRB-approved retrospective analysis. Data are from the National Alzheimer's Coordinating Center Uniform Dataset from 42 Alzheimer's Disease Research Centers. Participants aged 40–95 years as of June 2023 with mild cognitive impairment (MCI) or dementia on baseline evaluation were included. Psychosis was defined as clinician-diagnosed visual or auditory hallucinations or delusions manifesting at the time of baseline evaluation. Ethnoracial groups were self-reported. Associations between ethnoracial groups and psychosis in NCDs were estimated using adjusted multivariable logistic regression with dichotomous measures of outcomes. Covariates included age, sex, years of education, severity of cognitive impairment (Clinical Dementia Rating scale), and presence or absence of any self-reported preexisting psychiatric illness. An analysis by age younger than 65 years was also conducted. Exploratory multivariable logistic regression analyses were performed for participants with milder stages of dementia (Clinical Dementia Rating 0.5 or 1) and for the subset of participants diagnosed with MCI. A total of 22,854 participants were included. The mean age was 73 + 9.7 years, and 50% were women. A total of 8,352 (37%) had MCI and 14,502 (63%) had dementia. In adjusted analysis, American Indian/Alaska Native (AI/AN) (OR 2.70, 1.75–4.17, p < 0.0001), Black-Latino (OR 2.33, 1.25–4.35, p = 0.0076), Other-Latino (OR 1.82, 1.42–2.33, p < 0.0001), Black, non-Latino (NL) (OR 1.66,1.47–1.87, p < 0.0001), and White-Latino (OR 1.42, 1.21–1.67, p < 0.0001) participants had greater odds of any psychotic symptom than White-NL participants. For age groups 40 to younger than 65 years, only Black-NL participants (OR 1.56, 1.13–2.14, p = 0.0064) were more likely to be diagnosed with any psychotic symptoms. For milder stages of dementia, Black-Latino (OR 3.44, 1.58–7.48, p = 0.0018), AI/AN (OR 2.73, 1.66–4.48, p < 0.0001), Other-Latino (OR 2.38, 1.72–3.30, p < 0.0001), Black-NL (OR 2.08,1.77–2.45, p < 0.0001), and White-Latino (OR 1.55, 1.23–1.95, p = 0.0002) participants had greater odds of psychosis in NCDs when compared with White-NL participants. For MCI alone, there were no significant differences. Black-NL, Latino, and AI/AN individuals were more likely to be diagnosed with psychosis in NCDs when compared with White-NL participants. More research is needed to explore sociocultural, psychosocial, and neuropathologic factors involved.
- 19 April 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (4) , e261-e262
Age effect in asymptomatic carotid stenosis in the CREST and ACT 1 stenting vs endarterectomy trials
- 19 April 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (4) , e261-e262
Age effect in asymptomatic carotid stenosis in the CREST and ACT 1 stenting vs endarterectomy trials
- 16 December 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 81 (4) , 938-944
Age effect in asymptomatic carotid stenosis in the CREST and ACT-1 stenting vs endarterectomy trials
- 16 December 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 81 (4) , 938-944
Age effect in asymptomatic carotid stenosis in the CREST and ACT-1 stenting vs endarterectomy trials
- 14 September 2024
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 33 (11) , 108004
Sex and outcomes after stenting and endarterectomy in asymptomatic severe carotid stenosis patients
- 14 September 2024
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 33 (11) , 108004
Sex and outcomes after stenting and endarterectomy in asymptomatic severe carotid stenosis patients
- Open Access
- 1 March 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 155, 55-61
The Challenge of Examining Social Determinants of Health in People Living With Tourette Syndrome
- 1 March 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 155, 55-61
Open AccessThe Challenge of Examining Social Determinants of Health in People Living With Tourette Syndrome
- 22 November 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (21) , e2378-e2384
Stroke Symptoms as a Surrogate in Stroke Primary Prevention Trials
Background and Objectives The use of surrogate end points can decrease sample size while maintaining statistical power. This report considers incident stroke symptoms as a surrogate end point in a post hoc analysis of asymptomatic patients from the multicenter, randomized Carotid Revascularization Endarterectomy vs Stenting Trial (CREST). Methods CREST assessed stroke symptoms using the Questionnaire for Verifying Stroke-free Status (QVSS) at baseline and follow-up. While the primary analysis of CREST defined “asymptomatic” as having been free of stroke/transient ischemic attack for 180 days, herein the population was further restricted by requiring no stroke symptoms at baseline. Incident adjudicated stroke was defined the same as for the primary analysis; incident stroke symptoms was defined as developing ≥1 stroke symptom in follow-up. Treatment differences between stenting (CAS) and endarterectomy (CEA) were assessed for 3 end points: adjudicated stroke, stroke symptoms, and adjudicated stroke or stroke symptoms. Results The cohort included 826 of the 1,181 asymptomatic patients in CREST. Adjudicated stroke events occurred in 44 patients, and incident stroke symptoms occurred in 183. Analysis of adjudicated stroke end points demonstrated a nonsignificant hazard ratio (HR) for CAS compared with CEA of 1.02 (95% CI 0.57–1.85). The corresponding HR for the incident stroke symptoms outcome was 1.54 (95% CI 1.15–2.08), and the HR for the composite outcome of adjudicated stroke or incident symptoms was 1.38 (95% CI 1.04–1.83), both significant. Discussion The low stroke event rates in asymptomatic patients challenges the assessment of CAS-versus-CEA treatment differences. Incorporating incident stroke symptoms as a surrogate outcome increased the number of events by over 4-fold. The analysis demonstrated a previously unreported significant difference in cerebrovascular risk with CAS compared with CEA. We propose that broadening the end points of primary stroke prevention trials to include surrogate events such as incident stroke symptoms could make trials more feasible.
- 22 November 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (21) , e2378-e2384
Stroke Symptoms as a Surrogate in Stroke Primary Prevention Trials
Background and Objectives The use of surrogate end points can decrease sample size while maintaining statistical power. This report considers incident stroke symptoms as a surrogate end point in a post hoc analysis of asymptomatic patients from the multicenter, randomized Carotid Revascularization Endarterectomy vs Stenting Trial (CREST). Methods CREST assessed stroke symptoms using the Questionnaire for Verifying Stroke-free Status (QVSS) at baseline and follow-up. While the primary analysis of CREST defined “asymptomatic” as having been free of stroke/transient ischemic attack for 180 days, herein the population was further restricted by requiring no stroke symptoms at baseline. Incident adjudicated stroke was defined the same as for the primary analysis; incident stroke symptoms was defined as developing ≥1 stroke symptom in follow-up. Treatment differences between stenting (CAS) and endarterectomy (CEA) were assessed for 3 end points: adjudicated stroke, stroke symptoms, and adjudicated stroke or stroke symptoms. Results The cohort included 826 of the 1,181 asymptomatic patients in CREST. Adjudicated stroke events occurred in 44 patients, and incident stroke symptoms occurred in 183. Analysis of adjudicated stroke end points demonstrated a nonsignificant hazard ratio (HR) for CAS compared with CEA of 1.02 (95% CI 0.57–1.85). The corresponding HR for the incident stroke symptoms outcome was 1.54 (95% CI 1.15–2.08), and the HR for the composite outcome of adjudicated stroke or incident symptoms was 1.38 (95% CI 1.04–1.83), both significant. Discussion The low stroke event rates in asymptomatic patients challenges the assessment of CAS-versus-CEA treatment differences. Incorporating incident stroke symptoms as a surrogate outcome increased the number of events by over 4-fold. The analysis demonstrated a previously unreported significant difference in cerebrovascular risk with CAS compared with CEA. We propose that broadening the end points of primary stroke prevention trials to include surrogate events such as incident stroke symptoms could make trials more feasible.
- 20 July 2022
- Published by Springer Nature
- p. 805-814
Masking of Trial Investigators
- 12 April 2022
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 63 (4) , e70-e71
Treatment of carotid stenosis in asymptomatic, non-octogenarian, standard risk patients with stenting versus endarterectomy trials
- 12 April 2022
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 63 (4) , e70-e71
Treatment of carotid stenosis in asymptomatic, non-octogenarian, standard risk patients with stenting versus endarterectomy trials
- 22 October 2021
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 75 (4) , 1276-1283.e1
Treatment of carotid stenosis in asymptomatic, nonoctogenarian, standard risk patients with stenting versus endarterectomy trials
- 22 October 2021
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 75 (4) , 1276-1283.e1
Treatment of carotid stenosis in asymptomatic, nonoctogenarian, standard risk patients with stenting versus endarterectomy trials